Future developments in the treatment of immune-mediated polyneuropathies

European Neurology

Volumn 38, Issue 3, 1997, Pages 230-237

  Van der Meche F G A ^a   van Doorn, P A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Chronic inflammatory demyelinating polyneuropathy; Corticosteroids; Guillain Barr syndrome, subgroups; Immunogobulins; Plasma exchange; Treatment

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN; STEROID;

ARTICLE; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; DEMYELINATING NEUROPATHY; DRUG MEGADOSE; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNOTHERAPY; PLASMAPHERESIS; POLYNEUROPATHY; PRIORITY JOURNAL; RECOMBINANT DNA TECHNOLOGY;

ADRENAL CORTEX HORMONES; AUTOIMMUNE DISEASES; CHRONIC DISEASE; CLINICAL TRIALS; DEMYELINATING DISEASES; FORECASTING; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; INFECTION; PLASMA EXCHANGE; POLYRADICULONEUROPATHY;

EID: 0030929978     PISSN: 00143022     EISSN: 14219913     Source Type: Journal    
DOI: 10.1159/000113378     Document Type: Article

References (64)

1. van der Meché FGA, Van Doom PA: Guillain-Barré syndrome and chronic inflammatory de-myelinating polyneuropathy: immune mechanisms and update on current therapies. Ann Neurol 1995:37:S14-S31.
2. Ad Hoc Committee WHO-AIREN: Acute Onset Flaccid Paralysis. Geneva. World Health Organization. 1993.
3. van der Meché FGA, Meulstee J, Vcrmeulcn M. Kievit A: Patterns of conduction failure in the Guillain-Barré syndrome. Brain 1988:111: 405-416.
4. Visser LH, van der Meché FGA, Van Doom PA, Meulstee J, Jacobs BC, Oomes PG, et al: Guillain-Barré syndrome without sensor loss (acute motor neuropathy). A subgroup with specific clinical, eleclrodiagnostic and laboratory features. Dutch Guillain-Barré Study Group. Brain 1995;118:841-847.
5. Jacobs BC, Van Doom PA, Schmitz PIM, Tio-Gillcn AP, Herbrink P, Visser LH, et al: Campylobacter jejuni infections and anti-GM 1 antibodies in Guillain-Barré syndrome. Ann Neurol 1996.
6. Griffin JW, Li CY, Ho TW, Xue P, Macko C, Gao GY, el al: Guillain-Barré syndrome in Northern China. The spectrum of neuropatho-logical changes in clinically defined cases (review). Brain 1995; 118:577-595.
7. Visser LH, van der Meché FGA, Meulstee J, Rolhbarth P, Jacobs BC, Schmitz PIM, et al: Cytomegalovirus infection and Guillain-Barré syndrome: the clinical, clectrophysiologic and prognostic features. Neurology 1996:47:668-673.
8. Feasby TE: Axonal Guillain-Barré syndrome. Muscle Nerve 1994:17:678-679.
9. van dcr Meche FGA, Meulstee J, Klevweg RP: Axonal damage in Guillain-Barre syndrome. Muscle Nerve 1991;14:997-1002.
10. Bcrciano J, Coria F, Monton F, Calleja J, Figols J, LaFarga M: Axonal form of Guillain-Barre syndrome: Evidence for macrophage-associat-cd demvclination. Muscle Nerve 1993; 16:744-751.
11. Kaldor J, Speed BR: Guillain-Barre syndrome and Campylobacter jejuni: A serological study. BrMcdJ 1984;288:1867-1870.
12. Rees JH, Soudain SF Gregson NA, Hughes RA: Campylobacter jejuni infection and Guillain-Barre syndrome. N Engl J Med 1995:333: 1374-1379.'
13. Chaudhry V, Corse AM, Comblath DR, Kuncl RW, Drachman DB, Freimer ML, el al: Multifocal motor neuropathy: Response to human immune globulin. Ann Neurol 1993:33:237-242.
14. Pcstronk A, Chaudhry V, Feldman EL, Griffin JW, Comblath DR, Denys EH, et al: Lower motor neuron syndromes defined by patterns of weakness, nerve conduction abnormalities, and high titers of antiglycolipid antibodies. Ann Neurol 1990:27:316-326.
15. Komberg AJ, Pestronk A, Bicser K, Ho TW, McKhann GM, Wu HS, et al: The clinical correlates of high-titcr IgG anti-GM I antibodies. Ann Neurol 1994:35:234-237.
16. Moran AP, Rictschcl ET, Kosunen TU, Zah-ringcr U: Chemical characterization of Campylobacter jejuni lipopolysaccharidcs containing n-acetylneuraminic acid and 2.3-diamino-2, 3-dideoxy-d-glucose. J Bacteriol 1991:173:618-626.
17. Yuki N, Taki T, Inagaki F, Kasama T, Takaha-shi M, Saito K, et al: A bacterium lipopolysac-charide that elicits Guillain-Barre syndrome has a GM1 ganglioside-like structure. J Exp Med 1993;178:1771-1775.
18. Oomes PG, Jacobs BC, Hazenberg MP, Banf-fer JR, van der Meche FGA: Anti-GM 1 IgG antibodies and Campylobacter bacteria in Guillain-Barre syndrome: Evidence of molecular mimicry. Ann Neurol 1995;38:170-175.
19. Corbo M, Quattrini A, Latov N, Hays AP: Localization of gml and gal(bcta l-3)galnac antigenic dctetminants in peripheral nerve. Necrology 1993:43:809-814.
20. Roberts M, Willison HJ, Vincent A, Ncwsom-Davis J: Multifocal motor neuropathy human sera block distal motor nerve conduction in mice. Ann Neurol 1995:38(1): 111-118.
21. Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I: Scrum ant i-GQ I b IgG ant ibody is associated with opthalmoplegia in Miller Fisher syndrome and Guillain-Barre syndrome: Clinical and immunohistochemical studies. Neurology 1993:43:1911-1917.
22. Willison HJ, Veilch J, Paterson G, Kennedy PG: Miller Fisher syndrome is associated with scrum antibodies to GQIb ganglioside. J Neurol Neurosurg Psychiatry 1993:56:204-206.
23. Yuli N, Sato S, Tsuji S, Ohsawa T, Miyatake T: Frequent presence of anti-GQ 1 b antibody in Fisher's syndrome. Neurology 1993:43:414-417.
24. Jacobs BC, Endtz HP, van der Meche FGA, Hazenberg M P, Achtercckle HAM, Van Doom PA: Scrum anti-GQ lb IgG antibodies recognize surface epitopes on Campylobacter jejuni from patients with Miller Fisher syndrome. Ann Neurol 1995:37:260-264.
25. Yuki N, Taki T, Takahashi M, Saito K, Yoshi-no H, Tai T, et al: Molecular mimicry between GQIb ganglioside and lipopolysaccharidcs of Campylobacter jejuni isolated from patients with Fisher’s syndrome. Ann Neurol 1994:36: 791-793.
26. Roberts M, Willison HJ, Vincent A, Newsom-Davis J: Serum factor in Miller Fisher variant of Guillain-Barre syndrome and neurotransmitter release. Lancet 1994;343:454-455.
27. Jacobs BC, Van Doom PA, Groenevcld JHM, Tio-Gillen AP, vander Meche FGA: Cytomegalovirus infections and anti-GM2 antibodies in Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry, in press.
28. Irie S, Saito T, Nakamura K, Kanazawa N, Ogino M, Nukazawa T, et al: Association of anti-gm2 antibodies in Guillain-Barre syndrome with acute cytomegalovirus infection. J Neuroimmunol 1996:68:19-26.
29. The Guillain-Barre Study Group: Plasmapheresis and acute Guillain-Barre syndrome. Neurology 1985;35:1096-1104.
30. French Cooperative Group on plasma exchange in Guillain-Barre syndrome: Efficiency of plasma exchange in Guillain-Barre syndrome: Role of replacement fluids. Ann Neurol 1987;22:753-761.
31. Dwyer JM: Manipulating the immune system with immune globulin (review). N Engl J Med 1992:326:107-116.
32. vander Meche FGA, Schmitz PIM, Dutch Guillain-Barre Study Group: A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. N Engl J Med 1992:326:1123-1129.
33. Hughes RAC: Randomised trial of plasma exchange. intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome. Lancet 1997:349:225-230.
34. Haass A, Trabert W, Gressnich N, Schintrigk K: High-dose steroid therapy in Guillain-Barre syndrome. J Neuroimmunol 1988:20:305-308.
35. Guillain-Barre Syndrome Steroid Trial Group: Double-blind trial of intravenous methylpred-nisolone in Guillain-Barre syndrome. Lancet 1993;341:586-590.
36. The Dutch Guillain-Barre Study Group: Treatment of Guillain-Barrd syndrome with high-dose immune globulins combined with methyl-prednisolone: A pilot study. Ann Neurol 1994; 35:749-752.
37. Asbury AK, Comblath DR: Assessment of current diagnostic criteria for Guillain-Barre syndrome (review). Ann Neurol 1990:27(suppl): S21-4.
38. Comblath DR, Asbury AK, Albers JW, Fcasby TE, Hahn AF, McLeod JG, et al: Research criteria for diagnosis of chronic inflammatory de-myelinating polyneuropathy (CIDP). Neurology 1991:41:617-618.
39. Hughes R, Sanders E, Hall S, Atkinson P, Colchester A, Payan P: Subacute idiopathic de-mvelinating polyradiculoneuropathy. Arch Neurol 1992;49:612-616.
40. Dyck PJ, Princas JW, Pollard JD: Chronic inflammatory demyelinating polyneuropathy; in Dyck T (ed): Peripheral Neuropathy, ed 3. Philadelphia. Saunders. 1993, pp 1498-1518.
41. Ilyas AA, Mithcn FA, Dalakas MC, Chen ZW, Cook SD: Antibodies to acidic glycolipids in Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 1992;107:111-121.
42. Lundkvist I, Van Doom PA, Vermeulen M, van Lint M, van Rood JJ, Brand A: Regulation of autoantibodies in inflammatory dentyeli-neating polyneuropathy: Spontaneous and therapeutic (review). Immunol Rev 1989; 110: 105-117.
43. Hartung HP, Reiners K, Schmidt B, Stoll G, Toyka KV: Serum intcrleukin-2 concentrations in Guillain-Barre syndrome and chronic idiopathic demyelinating polyradiculoneuropathy: Comparison with other neurological diseases of presumed immunopathogenesis. Ann Neurol 1991;30:48-53.
44. Hartung HP, Hughes RA, Taylor WA, Heinin-ger K, Reiners K, Toyka KV: T cell activation in Guillain-Barre syndrome and in ms: elevated serum levels of soluble IL-2 receptors. Neurology 1990:40:215-218.
45. Prineas JW, McLeod JG: Chronic relapsing polyneuritis. J Neurol Sci 1976;27:427-458.
46. McCombe PA, Pollard JD, McLeod JG: Chronic inflammatory demyelinating polyradiculoneuropathy. A clinical and electrophysio-logical study of 92 cases. Brain 1987; 110:1617-1630.
47. Dyck PJ, Lais AC, Ohta M, Bastron JA, Okazaki H, Groover RV: Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc 1975:50: 621-637.
48. Dyck PJ, O'Brien PC, Oviatt KF: Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol 1982; 11:136-141.
49. Barohn RJ, Kissel JT, Warmolts JR, Mcndell JR: Chronic inflammatory demyelinating polyradiculoneuropathy: Clinical characteristics, course, and recommendations for diagnostic criteria. Arch Neurol 1989;46:878-884.
50. DeVivo DC, Engel WK: Remarkable recovery of a steroid-responsive recurrent polyneuropathy. J Neurol Neurosurg Psvchiatrv 1970:33: 62-69.
51. Dyck PJ: Intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy and in neuropathy associated with igm monoclonal gammopathy of unknown significance (editorial). Neurology 1990:40:327-328.
52. Dyck PJ, Daube J, O'Brien P, Pineda A, Low PA, Windcbank AJ, ct al: Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 1986:314:461-465.
53. Hahn AF, Bolton CF, Pilay N, Chalk C, Ben-stead T, Bril V, et al: Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain 1996:119:1055-1066.
54. Vermeulen M, van der Meche FG, Speelman JD, Weber A, Busch HF: Plasma and gammaglobulin infusion in chronic inflammatory polyneuropathy. J Neurol Sci 1985;70:317-326.
55. Van Doom PA: Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy (review). J Neurol Neurosurg Psychiatry 1994;57(suppl): 38-42.
56. Van Doom PA, Vermeulen M, Brand A, Mulder PG, Busch HF: Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: Clinical and laboratory characteristics associated with improvement. Arch Neurol 1991:48:217-220.
57. Van Doom PA, Brand A, Strcngers PF, Mcul-stee J, Vermeulen M: High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind. placebo-controlled, crossover study. Neurology 1990;40:209-212.
58. Vermeulen M, Van Doom PA, Brand A, Stren-gers PFW, Jcnnchens FGI, Busch HFM:Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1993;56:36-39.
59. Hahn AF, Bolton CF, Zochodne DW, Feasby TE: Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. Brain 1996;! 19:1067-1077.
60. Dyck PJ, Litchy WJ, Kratz KM, Suarez GA, Low PA, Pineda AA, et al: A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994:36:838-845.
61. Thornton CA, Griggs RC: Plasma exchange and intravenous immunoglobulin treatment of neuromuscular disease (review). Ann Neurol 1994;35:260-268.
62. The French Cooperative Group on Plasma Exchange in Guillain-Barre Syndrome. Appropriate number of plasma exchanges in Guillain-Barre syndrome. Ann Neurol 1997, 41: 298-306.
63. Newburger JW, Takahashi M, Beiser AS, Bums JC, Bastian J, et al: A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute kawa-saki syndrome. N Engl J Med 1991:324:1633-1639.
64. Van dcr Meche FGA, Van Doom PA: The current place of high-dose immunoglobulins in the treatment of neuromuscular disorders. Muscle Nerve 1997:20:136-147